BI Asset Management Fondsmaeglerselskab A S Sells 13,820 Shares of Insulet Co. (NASDAQ:PODD)

BI Asset Management Fondsmaeglerselskab A S trimmed its position in Insulet Co. (NASDAQ:PODD) by 74.7% during the 1st quarter, HoldingsChannel reports. The firm owned 4,680 shares of the medical instruments supplier’s stock after selling 13,820 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Insulet were worth $802,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Sunbelt Securities Inc. bought a new stake in Insulet during the first quarter worth approximately $29,000. Wolff Wiese Magana LLC increased its stake in Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 134 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in Insulet during the fourth quarter worth approximately $34,000. Jones Financial Companies Lllp bought a new stake in Insulet during the fourth quarter worth approximately $40,000. Finally, Lindbrook Capital LLC increased its stake in Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after acquiring an additional 75 shares during the last quarter.

Insider Transactions at Insulet

In related news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the transaction, the director now directly owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the sale, the director now directly owns 42,586 shares in the company, valued at $7,703,807.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,931 shares of company stock valued at $2,636,286. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Down 1.3 %

Shares of PODD stock traded down $2.48 during trading hours on Wednesday, reaching $192.69. 89,319 shares of the company’s stock were exchanged, compared to its average volume of 854,453. The stock’s 50 day moving average is $187.72 and its 200-day moving average is $185.61. The company has a market cap of $13.50 billion, a price-to-earnings ratio of 59.14, a P/E/G ratio of 3.58 and a beta of 1.16. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $293.64.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to the consensus estimate of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 earnings per share. Analysts predict that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of several analyst reports. Jefferies Financial Group boosted their price objective on Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Canaccord Genuity Group boosted their target price on Insulet from $226.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 target price for the company in a research report on Tuesday, May 7th. Raymond James dropped their target price on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Finally, OTR Global restated a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $239.18.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.